^
Association details:
Biomarker:FLT3-ITD mutation
Cancer:Acute Myelogenous Leukemia
Drug:DT-061 (PP2A inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

PP2A-activating drugs enhance FLT3 inhibitor efficacy through AKT inhibition-dependent GSK-3ß-mediated c-Myc and Pim-1 proteasomal degradation

Published date:
02/10/2021
Excerpt:
...co-treatment of FLT3-ITD-expressing cells with FLT3 inhibitors and PP2A-activating drug (PADs), which are in development. PADs, including FTY720 and DT-061, enhanced FLT3 inhibitor growth suppression and apoptosis induction in FLT3-ITD-expressing cell lines and primary AML cells in vitro and MV4-11 growth suppression in vivo.
Secondary therapy:
FLT3 inhibitor
DOI:
10.1158/1535-7163.MCT-20-0663